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Abstract
Background This report describes two cases with unex-
plained positive results for phencyclidine (PCP).
Aims This case will correlate lamotrigine (Lamictal®) use
with false-positive results for PCP on a rapid urine
toxicology screen.
Methods Case 1: A 62-year-old male arrived to the
emergency department in extreme psychosis. All positive
results on the urine drug screen could be accounted for
except PCP. A comprehensive drug screen was performed
to confirm PCP use, but returned negative. PCP was ruled
out as the causative agent. The reason for the PCP false
positive remained unknown. Case 2: A 49-year-old female
presented to the ED with a history of seizures and
depression. Despite positive PCP results on a rapid urine
drug screen, PCP use was ruled out due to patient
presentation and comprehensive history.
Results The differential diagnosis in case 1 included PCP
abuse until PCP was ruled out by a comprehensive drug
screen. A literature search failed to explain a reason for
false-positive results. The patient in case 2 was not
psychotic, but returned a positive urinalysis result for
PCP. Case 2’s presentation combined with a comprehensive
history at the facility ruled out PCP use. Both patients were
taking the anti-seizure medication lamotrigine with nothing
else in common.
Conclusion Lamotrigine has the potential to cause false-
positive results for PCP on the Bio-Rad TOX/See urine
toxicology screen.
Keywords Phencyclidine (PCP).False positive.
Lamotrigine (Lamictal).Drugs of abuse.
Rapid urine drug screen.Toxicology
Introduction
Modern rapid urine drug testing kits sometimes provide
false-positive results that may cloud clinical pictures. This
report describes two patients presenting to the emergency
department (ED) with unexplained positive results for
phencyclidine (PCP) on a rapid urine toxicology screen.
Background
Case 1 A psychotic 62-year-old male arrived to the ED
extremely agitated with violent behavior. The
patient’s wife described a history of narcotic
abuse, violent behavior, self harm, and lighting
fires in the house and yard. She expressed extreme
worry and feared for both their safety. The patient
was uncooperative, delirious, and required seda-
tion and soft restraints to prevent injury to himself
and staff.
The patient was examined by the ED physician
and found to be in good physical health with no
obvious trauma. The patient had no prior history
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able. Vital signs were stable, and CBC and Chem-
7 were unremarkable, with the exception of a high
blood glucose at 244 mg/dl. A rapid urine drugs
of abuse (DOA) screen (Bio-Rad TOX/See test
kit) returned positive results for methadone, oxy-
codone and PCP. Methadone and oxycodone were
both part of the patient’s home medication
regimen (see Fig. 1). The patient was unable to
reliably state what medications he had ingested
recently and whether or not he used recreational
drugs. The patient’s home medication bottles were
brought by the wife to the ED. Investigation
revealed that pill counts corresponded with latest
medication fill, likely indicating proper use and
ruling out an apparent intentional overdose using
prescription medications. Positive results on the
urine DOA for oxycodone and methadone were
expected. Negative results for benzodiazepines
could possibly be explained by an “as needed”
use of the medications and/or the fact that
some urine tests have an inability to detect
clonazepam [1]. The positive PCP result was
unexpected.
Patient age and current local usage trends argued
against PCP intoxication, whereas the history of
drug abuse, violent behavior and delusions justified
sending a urine sample for a comprehensive drug
screen. Contrasting with the rapid urine DOA
screen, the colorimetric comprehensive screen
detected benzodiazepines, methadone, oxycodone
and oxymorphone. PCP was not detected. The
reason for the PCP false positive remained
unknown. Patient records were eventually located
at another institution and revealed a history of
mental instability. PCP was ruled out as a
causative agent.
Case 2 Weeks later, a 49-year-old female was transported to
the ED by ambulance. The patient had a history of
bipolar and depressive disorders as well as a history
of seizures. As the patient arrived on a stretcher, she
was somnolent but in no acute distress. She was
examined by the ED physician and found to be in
good general health with no pain or obvious trauma.
The patient’smotherstatedthatherdaughtersaidher
tongue felt swollen then she became stiff and fell to
the floor. Upon initial examination, the patient had a
blunt affect and some rigidity in her extremities; she
also felt nauseous. CBC and Chem-7 were unre-
markable. A rapid urine DOA screen (Bio-Rad
TOX/See test kit) revealed positive results for
benzodiazepines and PCP. The positive result for
benzodiazepines was expected as the patient was
taking alprazolam; the positive result for PCP was
unexpected.
As the patient became more aware, she reported
having felt disorientated for 2 days prior and
experienced involuntary jerking and seizure-like
activity that morning. She stated that she is
adherent to her prescribed medication regimen and
that she does not abuse recreational drugs or
prescription medications. The patient manages her
Case #1 − Home Medications 
Generic Name  Brand Name Dose  Route Frequency 
Clonazepam  Klonopin
®  0.5 mg  PO  Three times daily 
Docusate Sodium  Colace
®  100 mg  PO  Daily 
Etodolac  Lodine
®  300 mg  PO  Two times daily 
*  Lamotrigine  Lamictal
 ®  150 mg  PO  Four times daily 
Methadone  Dolophine
®  10 mg  PO  Four times daily 
Oxycodone  Roxicodone
®  30 mg  PO  Three times daily 
Potassium Chloride  K-Dur
®  20 mEq  PO  Daily 
Pregabalin  Lyrica
®  150 mg  PO  Three times daily 
Rosuvastatin  Crestor
®  5 mg  PO  Daily 
Temazepam  Restoril
®  7.5 mg  PO  Bedtime as needed
Topiramate  Topamax
®  100 mg  PO  Two times daily 
Tramadol  Ultram
®  50 mg  PO  1-2 tablets daily 
 
Case #2 − Home Medications 
Generic Name  Brand Name Dose  Route Frequency 
Alprazolam  Xanax
®  1 mg  PO  Two times daily 
Fluoxetine  Prozac
®  40 mg  PO   Daily 
*  Lamotrigine  Lamictal
 ®  100 mg  PO   Two times daily 
Oxcarbazepine  Trileptal
®  300 mg  PO  Two times daily 
Fig. 1 Patient home
medications
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prescription medications (see Fig. 1). A serum
lamotrigine level was sent to document use and
resulted in a value of 7.6 mcg/ml (reference range
0.25-29.1 mcg/ml) [2]. Recently the patient had
been prescribed a new medication, oxcarbazepine
(Trileptal®), to assist in controlling her seizure
disorder. She did not use any herbal remedies and
had no recent use of over-the-counter products.
The patient had a consistent history of treatment
at the facility, and the use of PCP by this patient
was ruled out. Likely, this patient suffered from
breakthrough seizure or an episode of tardive
dyskinesia because of the addition of the new
medication. The patient was discharged home the
same day with instructions to follow-up with her
neurologist.
Discussion
PCP was developed in the 1950s as an intravenous
anesthetic. Its use was discontinued due to dramatic and
intense side effects, including hallucinations, delusions,
anxiety and agitation. PCP has no current medical use, but
is sold illicitly in multiple forms. Under the influence of
PCP, users hallucinate and exhibit rapid, intense emotional
swings. Abusers can experience unpleasant psychological
effects with symptoms mimicking schizophrenia (delusions,
hallucinations, disordered thinking, extreme anxiety) [3].
Yago et al. reported that 50% of individuals brought to the
ED because of PCP use have significant anxiety combined
with a variety of psychotic clinical symptoms bordering on
mania, depression and/or schizophrenia [4]. PCP can be
seen in the urine 4-6 h after use and can be detected for up
to 14 days [5].
A current rise in PCP abuse combined with violent crime
has made recent headlines in Washington, DC. Police report
that violent crimes involving PCP use have increased 9%
from 2007. Drug addicts appear to be looking for a longer
lasting high. A crack cocaine high lasts only minutes; PCPs
effects can last from 3-6 h [6]. The Monitoring the Future
Survey conducted annually by the University of Michigan’s
Institute for Social Research found that in 2007, 6.1 million
persons aged 12 or older have used PCP. In 2008, 1.8% of
high school seniors admitted using PCP in their lifetime,
while past-year use was reported at 1.1% [7].
The advent of rapid urine screening tests for drugs of
abuse has provided the clinician with access to quick
information regarding a battery of potential drugs of abuse
that patients might have had exposure to, ingested, inhaled
or used intravenously. Rapid screen kits are calibrated and
have cut off concentrations as decided by the Department of
Health and Human Services (DHHS) Substance Abuse
Mental Health Services Administration (SAMSHA) [8–10].
Bio-Rad’s TOX/See test kit is a urine-based, lateral flow
chromatographic immunoassay. It is a one-step, hand-held,
point-of-care test device for the qualitative detection of 14
drugs and their metabolites in human urine. The TOX/See
guide states results are available in 5 min after application
of urine to the test kit, with results remaining stable for up
to 1 h afterwards [5].
The patient in case 1 presented to the ED in psychotic
duress. Urine was collected via straight catheterization. The
Bio-Rad Laboratories TOX/See rapid urine test was used
and returned the positive result for PCP. The comprehen-
sive drug screen returned negative for PCP and overturned
the hypothesis that the psychosis was related to PCP use.
The Bio-Rad Tox/See package insert was consulted and
made no mention of possible cross reactants with phency-
clidine [5]. A literature search was conducted to see if any
of the home medications might cause a false positive.
Searches were conducted using PubMed and various
combinations of search terms: “phencyclidine,”“ PCP,”
“false,”“ positive,”“ urine” and “test.” Also included was
a search on false positives reported on all generic and brand
names of home medications the patient was reportedly
ingesting. Results showed six case reports documenting
venlafaxine (Effexor®, Wyeth) and dextromethorphan
(DM) as known agents that cause false positives for PCP
on rapid urine drug tests [11–17]. The patient was not on
venlafaxine, and according to the Bio-Rad package insert,
DM does not cross react at a concentration of 100 mcg/m-,
so an over-the-counter overdose of DM could be eliminated
(although DM is known to cross react in 4 of 8 commonly
marketed kits) [1, 5].
A single case report with chloroquine and one postmor-
tem tramadol (Ultram®) urine specimen showed false
positives for PCP [18, 19]. This patient was not known to
be on chloroquine but was taking tramadol at home. Hull
and colleagues reported a false positive for PCP involved in
a fatal single-drug overdose involving tramadol. They
measured a serum tramadol level of 14 mg/l, orders of
magnitude above therapeutic ranges and the highest
tramadol level reported at the time of the case [19]. Their
experiment demonstrated that the false positive for PCP
was due to the extremely high level of tramadol. Further,
they showed that lower levels of the medication resulted in
cutoff values below positive results for PCP on their test,
demonstrating the false positive in that case was due to
their specific immunoassay combined with the extremely
high level of tramadol. In the present case, there was no
evidence of intentional or accidental overdose with trama-
dol, as the pill counts corresponded with the medication fill
date and prescription instructions on the pill bottle. Our
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induced respiratory depression. Tramadol was not sus-
pected as a causative agent for the psychosis, and a serum
tramadol level was not obtained.
As a thorough literature search and the test kit package
insert failed to provide possibilities for the positive PCP
result, Bio-Rad technical support was contacted. Our query
was elevated to a specialist who later provided a copy of the
Bio-Rad TOX/See Cross Reactivity Guide. The unpub-
lished guide lists venlafaxine as a “potential” cross reactant
and lamotrigine (Lamictal®, GlaxoSmithKline) as the only
known medication to cause false-positive results for PCP
on their rapid urine screen [20]. Bio-Rad’s guide is a
manufacturer document and does not reference any specific
cases, measured cutoff values for the drugs, or any
scientific data on why or how these cross react. There are
multiple published case reports in the literature describing
venlafaxine-induced false positives for PCP; there are none
for lamotrigine.
The patient in case 2 presented to the ED via ambulance
andwasarousableuponarrival.Shewasnotaltered,psychotic
or under duress. Blood and urine samples were provided
willingly by the patient. The Bio-Rad Laboratories TOX/See
point-of-care rapid urine test was used to assess potential
DOA and the positive benzodiazepine and PCP results
returned shortly thereafter. Based on current symptoms and
history at the facility, recreational PCP abuse was not
considered as a differential diagnosis. The patient provided a
logical sequence of events and denied use of any illicit drugs,
over-the-counter medications and/or herbal remedies. A
literature search was conducted on all generic and brand
names of her prescriptions. None were implicated in
providing false-positive results on any DOA screen. The
patient was taking her prescribed lamotrigine as verified by a
serum level of 7.6 mcg/ml. Due to the patient presentation,
comprehensive history at the facility, current PCP usage
trendsandinformationprovidedbyBio-Rad’s cross-reactivity
guide,PCPusewasruledout,andthefalse-positiveresultwas
blamed on lamotrigine.
Results
Lamotrigine is the common bond that links these two cases
with regards to the false-positive results for PCP. During case
1 the patient was actively psychotic, and recreational drug use
needed to be ruled out through the comprehensive drug
screen. No previous documentation in the literature was able
to explain the false positive for PCP until the manufacturer
was contacted. Case 2 provided evidence that illicit drug use
was not involved with the positive result, and a lamotrigine
serum level established that the patient was compliant with
her home medications.
Conclusion
Lamotrigine has the potential to provide a false-positive
result for PCP on the Bio-Rad TOX/See rapid urine
toxicology screen. Aside from the unpublished Bio-Rad
cross-reactant list, which is available from the company
technical support division on request, this is the first known
report published in the medical literature that describes this
cross reaction. Clinicians wishing to rule out PCP-induced
psychosis should be aware of this potentially confounding
result. The clinical symptoms of delirium, agitation and
psychosis may not be attributable to PCP if the patient is
taking lamotrigine. Further research is warranted to eluci-
date the basis for the false-positive PCP result caused by
lamotrigine on this and other rapid urine DOA assays.
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